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Abstract: We evaluated the effect of combination anti-retroviral treatment (cART) on the 
host control of EBV infection in moderately immunosuppressed HIV-1 patients. Twenty 
HIV-1 infected individuals were followed for five years with repeated measurements of 
EBV DNA load in peripheral blood lymphocytes in relation to HIV-RNA titers and CD4+ 
cell counts. Individuals with optimal response, i.e. durable non-detectable HIV-RNA, 
showed a decline of EBV load to the level of healthy controls. Individuals with non-
optimal HIV-1 control did not restore their EBV control. Long-lasting suppression of   
HIV-replication after early initiation of cART is a prerequisite for re-establishing the 
immune control of EBV. 
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1. Introduction 
Before the introduction of effective combination anti-retroviral treatment (cART) of HIV-1 
infection in 1996, HIV-infected patients had an over a 1000-fold increased risk of developing non-
Hodgkin lymphomas (NHL) [1,2]. Such an increased risk of NHL was previously observed among 
post-transplant patients [3,4]. The pathogenic role of Epstein Barr virus (EBV) in the development of 
those malignancies is of great concern. In HIV-1 infected individuals, almost all primary central 
nervous system lymphomas are EBV positive [5,6]. In contrast, HIV-associated peripheral lymphomas 
display a lower frequency of EBV positivity [7]. EBV latency associated genes, Epstein-Barr nuclear 
antigens (EBNA)-1, EBNA-2 and latent membrane protein (LMP) have been expressed in varying 
frequencies in the lymphomas of HIV-infected patients. The role of disrupted immunosurveillance and 
T-cell immunity in the control of EBV replication was shown early in the epidemic [8]. After the 
introduction of cART, a general improvement of immune function in HIV-infected patients was 
observed, together with a significant decrease of NHL [9]. In AIDS patients, an association between EBV 
DNA load and the loss of EBV-specific CD8+ T cell function has been demonstrated [10]. There is also a 
correlation between EBV DNA load, numbers of CD4+ cells, and numbers of functional T-cells [10]. 
During the pre-cART period, we analyzed EBV load in several subgroups of HIV-infected patients. A 
particularly prominent increase in EBV load (40–50-fold) was seen in patients participating in a 
placebo controlled trial with recombinant gp-160 vaccine. Twenty HIV-patients with moderate 
immune deficiency, who had previously taken part in this trial [11], were regularly tested during a five 
year follow up. The virological and immunological effects of cART measured by HIV-1 RNA titers 
and CD4+ cell counts were analyzed in relation to EBV load. 
2. Results and Discussion  
In the samples from HIV-infected patients, the EBV load varied considerably with a range between 
0.003 to 6700 EBV DNA copies per 1000 B-cells (approximately 250,000-fold difference). The   
intra-individual variation was much lower (approximately 2500-fold difference). Four patients showed 
a very high EBV load (>100) on at least one occasion. In contrast, all repeated values were below 0.6 
EBV copies per 1000 B-cells (median 0.05: range: 0.01–0.6) in 10 HIV-negative controls. The intra-
individual variation seen in the control group was less than two-fold.  
Based on the HIV-1 RNA levels, there were three main patterns crystallized regarding the patients 
virological and immunological response to cART and the impact of the treatment on the EBV load. 
Group I showed HIV-1 RNA levels constantly below the detection limit after initiation of cART, 
indicating optimal inhibition of HIV-1 replication. Patients of group II had most but not all HIV-1 
RNA levels below the detection limit; while in group III almost all values were above the detection 
limit. There was no difference in the frequency of HIV-RNA measurements between the three groups. 
Three patients were lost to extended follow up and one patient was treated only with a single NRTI-
drug. These patients were excluded from this analysis. There were no differences in gender, median 
age, route of transmission or ethnicity between the groups. 
After 1–2 years of cART treatment, all patients in group I (n = 5) showed a decrease in the EBV- 
load, which approached levels seen in healthy controls. However, some group I patients showed a 
temporary increase of EBV-DNA load during the second year after the initiation of cART (Figure 1a). Viruses 2010, 2                  
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Figure 1. The effect of cART treatment on CD4 counts and EBV load over time. Upper 
limit of EBV load in healthy controls is stipled and time before cART is shadowed. (a) 
EBV load in group I (with constant undetectable HIV-values after introduction of cART) 
and (b) CD4 levels in group I. (c) EBV load in group II (with most but not all HIV-values 
below detection limit after introduction of cART) and (d) CD4 levels in group II. (e) EBV 
load group III (with most HIV-RNA values above detection limit after introduction of 
cART) and (f) CD4 levels group III. 
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The patients in group I showed increased median CD4+ cell counts: from 285 × 10
6/L during the 
year before cART (subsequently called pre-treatment levels) to 530 × 10
6/L (p < 0.05) at the end of the 
study (Figure 1b).  
Figures 2a and 2b exemplify two individuals from group I. These two patients differed in their 
initial CD4 status: one had a median pre-treatment CD4+ cell count of 200 × 10
6/L and the other a 
median pre-treatment CD4+ count of 380 × 10
6/L. In the more immunodeficient patient, the EBV 
control seemed initially absent and an initial increase of the EBV load was seen. However, after two 
years of cART treatment the levels of the EBV load decreased. The second patient, with higher initial 
CD4+ cell counts, displayed an EBV load comparable to that seen in healthy individuals both before 
and during cART treatment.  
Figure 2. Examples of individual responses of patients from all three groups. EBV load 
(10-log) (dashed line), HIV-RNA titer (10-log) (solid line), and CD4+ cell count (dotted 
line) over time. Time 0 is defined as the start of cART. Time before cART is shadowed. 
Panel (a) and (b) represent two patients from group I. Patient A had CD4+ cell count of 
200 × 10
6/L the year before cART; patient B had a median CD4+ cell count of 380 × 10
6/L 
the year before cART. (c) Example of a patient from group II. (d) Example of a patient 
from group III. 
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Patients in group II (n = 5) showed a continuous improvement of CD4 cell counts without 
restoration of EBV control, i.e., no decrease of the EBV load (exemplified in Figure 2c). In these 
patients, the CD4+ cell counts increased during treatment from a median pre-treatment value of   
180 × 10
6/L to 570 × 10
6/L (p < 0.05) at the end of the study. In this group, the two patients with the 
highest pre-treatment CD4+ cell counts had a slightly lower EBV load at the end of observation time 
than before treatment, while the others showed a variable pattern with no consistent decrease in the 
EBV load (Figure 1c respectively Figure 1d). 
Figure 3. Box plot representing median values and distribution of EBV load in patients 
grouped according to HIV-RNA response after initiation of cART. Maximum EBV load 
and EBV load at the end of the study (>1.5 years after introduction of treatment initiation) 
in relation in groups I and III. The boxes represent 50% of patients in first quartile to third 
quartile. Bars under and above the boxes represent distribution of all the values. The 
horizontal line marks the median. 
 
 
In group III (n = 6), the EBV load was high and showed a fluctuation, which indicated poor 
virological and immunological control (Figure 1e). Only a moderate increase in CD4+ cell counts was 
observed: from the median pre-treatment value of 200 × 10
6/L to 240 × 10
6/L at the end of the study 
(Figure 1f). This might be due to an incomplete response to treatment (as exemplified in Figure 2d). 
For more than one year preceding the initiation of treatment with protease inhibitor (PI) or other drugs 
from the non-nucleoside analog reverse transcriptase inhibitors (NRTIs) category, all group III patients 
had been treated with one or two NRTIs. Four of these patients showed an increase in the EBV-DNA 
levels during study period. The effect on EBV load is summarized in Figure 3. We further analyzed EBV Viruses 2010, 2                  
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response in relation to CD4+ levels before treatment (Figure 4). For this purpose, the patients with 
sufficient number of CD4-count measurements were divided in two groups according to the median 
pre-treatment CD4+ cell count (below and above 200 × 10
6/L). There were six and 13 patients in the 
low and high CD4-count groups, respectively. The median peak EBV value, i.e., the highest value 
detected, was one 10-log higher in the group with low CD4 levels when compared to those with high 
CD4 levels. The median EBV load one year after the initiation of cART was within normal range in 
the group with higher pre-treatment CD4 levels, but remained high in the patient group with lower 
CD4 values.  
Although the association between HIV-1 infection and the development of lymphoma was noted 
early in the epidemic [12,13], the pathogenic mechanisms have not been clarified. Immune suppression 
as well as a general immune activation is likely to play a crucial role in the pathogenesis [14]. In 
addition, EBV is considered to be a strong predisposing, or even a causative, factor. Transplant 
patients represent another group with a high risk of EBV-positive NHL. In these patients, the constant 
immune modulation with modern immune suppressants in combination with minor mismatches may 
explain the high NHL risk [15]. EBV load has been suggested as a predictor for risk of 
lymphoproliferative disease in this group [16–18]. 
Figure 4. Box plot representing median values and distribution of EBV load in patients 
grouped according to median CD4 values and patient grouping. A) Maximum EBV load 
(Max) and EBV load at one year after introduction of cART (End), respectively, in patients 
with CD4+ cell count median values <200 × 10
6/L (n = 6) and > 200 × 10
6/L (n = 13) 
during the 12 months before introduction of cART. The boxes represent 50% of patients in 
first quartile to third quartile. Bars under and above the boxes represent distribution of all 
the values. The horizontal line marks the median. 
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After the introduction of cART in 1996, the incidence of HIV-related NHL has been considerably 
reduced [19]. In the current study, we observed differences between various groups of cART treated 
HIV patients in the dynamics of the balance between EBV infection and host response, in relation to 
the pre-treatment CD4 levels and the efficiency of cART in controlling HIV-RNA levels. We noticed 
some patients with an incomplete EBV control, who had an adequate effect of cART treatment on the 
HIV-1 RNA levels. Our results may indicate that an HIV-induced immune dysregulation persists even 
after reduction of HIV-1 load to undetectable levels [14]. Similar to other studies , we noticed a lack of 
EBV control in patients with an initially low CD4+ cell count (<200 × 10
6/L) and labile virological 
response to cART [20], sometimes resulting in a biphasic EBV response. This phenomenon is similar 
to hepatitis B, hepatitis C and Varicella-Zoster virus flares, which were earlier described in the process 
of immune restoration in HIV-patients following cART treatment [21]. It is likely that an increased 
lymphoma risk remains during the period with high EBV load and probably exists until the 
establishment of permanent EBV control as also suggested by others [22,23]. In patients with non-
successful HIV-therapy this risk may be more pronounced due to the higher EBV DNA levels. The 
latter phenomenon is exemplified both by patients with most HIV RNA values as well as those with 
some HIV values just above the detection limit. It is also in line with the most recent international 
recommendation to initiate antiretroviral therapy when CD4+ cell counts fall below 350 × 10
6/L to 
prevent a decrease to values as low as 200 × 10
6/L. However, consequences of persistent high EBV-
DNA load in each individual HIV-infected patient have not yet been elucidated. If high EBV load 
precedes lymphoma, the results of our study might indicate a need for EBV-monitoring in patients 
initiating cART with CD4 values below 200 × 10
6/L and in non- successfully treated HIV-infected 
patients. Patients at risk for NHL could be identified at an earlier stage by monitoring EBV load, as is 
routinely done in post-transplant patients [18,24,25]. However, the nature of EBV infection in HIV-
positive subjects is very different from that in post-transplant patients. In these (re-)appearance of 
EBV-specific CD8(+) T cells leads to an immediate decrease in EBV load [26].  This may be due to 
that the HIV carriers have a continuous exhaustive deregulation of the normal B cell biology and a 
reduction in immunity plays a role in developing NHL. In post-transplant patients, a modified 
immunosuppressive therapy or an antiviral EBV-treatment can prevent the development of 
malignancies from a preceding polyclonal lymphoproliferative disease [24,25]. However, the 
lymphoma risk did not increase during a long term follow up in a group of HIV-1 infected patients 
with temporarily high EBV load in PBMC [27]. None of our patients developed lymphoma during the 
follow up period of two to six years, although some patients showed extremely high EBV load values. 
This is interesting since a combination of high EBV load with the reduced function of specific EBV-
reactive T-cells has been suggested to affect the risk of NHL [10]. 
Similar to our results, Righetta et al. [20] observed an elevated EBV load as well as a biphasic EBV 
response after cART initiation in a study of highly immunocompromised HIV-1 patients. They also 
observed a correlation between an increase of EBV-DNA and anti-EA or anti-VCA. In a study by 
Stevens et al. [28], no difference in the EBV load was detected between patients with and without 
cART. In this study, the median time of cART treatment was only 13 months. According to our 
observations, this is an insufficient time for re-establishing EBV control. The absence of restored EBV 
control is also reflected in serologic analysis where anti-EBNA-IgG was reduced and anti-VCA-IgG 
increased as shown by others [20]. Viruses 2010, 2                  
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3. Experimental 
3.1. Patients 
Twenty HIV-infected patients, selected from a recombinant gp-160 vaccine trial, were followed 
with repeated analyses of the EBV load, HIV-RNA titer and CD4+ cell counts, at Karolinska 
University Hospital, Huddinge (KUHH), between 1995 and 2000. At inclusion, the median CD4+ cell 
count was 255 × 10
6/L (range 120–480) and the first analysis of HIV-RNA done in the end of 1995 or 
the beginning of 1996 showed a median value of 37,000 copies/mL (range <500–1,200,000). In 
Table 1 we summarize the clinical characteristics of the patients. HIV negative controls were recruited 
among healthy laboratory staff and were not matched for age, sex, or risk group. 
The cART treatment was initiated and given independently of this study according to clinical practice. 
Table 1. Demographic patient data and route of transmission 
(1). 
Patients  n 
Number of patients  20 
Females  3 
Median age  40(31–65) 
Route of infection   
Heterosexual  9 
MSM*  10 
Unknown  1 
Origin   
Northern Europe  15 
Africa  5 
* Men who have sex with men. 
(1) Patients were divided in three groups based on HIV-load. There were no differences in gender, 
median age and route of transmission between the groups. Group I: constant undetectable HIV-
values after introduction of cART. Group II: most but not all HIV-values below detection limit 
after introduction of cART: Group III: almost all HIV-RNA values above detection limit.  
 
Blood samples for EBV-analysis (20 mL) were drawn after informed consent at the time of the 
regular visits to the open HIV-ward at KUHH, with 6–12 months intervals. We collected two to six 
samples from each patient. In 1999, complete EBV-serology was analyzed using frozen plasma 
samples collected during the same year from all the patients. 
All 20 patients had IgG-antibodies to VCA and to EBNA as a result of the EBV-carrier status. 
Sixteen of the patients also had detectable anti-EA-titers. While the anti-EBNA titers were within 
normal range, the anti-VCA and anti-EA titers were elevated in the majority of the patients (anti-VCA 
GMT: 960, range 1:160–5120; anti-EA GMT: 80, range: 1:20–640). At the time of sampling for 
serology, the median CD4+ cell count was 365 × 10
6/L (170–1010). The CD4+ cell counts, HIV-RNA 
values, and clinical data were collected from patient files.  
None of the patients were diagnosed with lymphoma or AIDS and no deaths occurred during the 
study period. Five patients were on ART at the start of the study (three on dual drug- and two mono-Viruses 2010, 2                  
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drug therapy). All patients except one received cART during the study period; 18 received 
combination therapy, with nucleoside reverse transcriptase inhibitor (NRTI) in combination with 
protease inhibitor and/or a non NRTI. One patient received only a dual NRTI combination, and one 
patient continued mono-therapy with azidothymidine. 
3.2. EBV-DNA Analysis  
CD19 positive B lymphocytes were isolated according to Ehlin-Henriksson et al. [29]. The enriched 
B cells were suspended in 100 μL PCR-lysate buffer [30]. The samples were then stored at −20 °C and 
proteinase-K was inactivated by heating for 15 minutes at 94 °C before PCR. PCR amplification of 
viral DNA was performed according to Gustafsson et al. [31] using a set of nested primers specific for 
the LMP1-promotor and its upstream control sequence (LRS) region (co-ordinates in B-95-8 prototype 
strain in parentheses): the outer primer pair was LSY: 5'-CCT TTC TAC GCT TAC ATG CAC ACA 
C-3' (169 678 to 169 654), and LAY: 5'-TGG ACA GAG AAG GTC TCT TCT GAA G-3' (169 239 to 
169 263); the inner primer pair was LSI: 5'-CTA CAT CCC AAG AAA CAC GCG TTA-3' (169 586 
to 169 561), and LAI: 5'-AAG CAT GAG AGC AAA GGA ATA GAG-3' (169 290 to 169 314). The 
EBV genome number was calculated according to Gustavsson et al. [31]. The EBV negative cell line 
BJAB [14], water and lysis buffer without DNA were included as negative controls. Namalwa cells 
with one EBV genome copy per cell were used as a positive control. [15]. Sensitivity of the PCR-assay 
was established to one genome.  
The method has been validated against Real-Time (RT-) PCR and the results correlated strongly. 
However RT-PCR occasionally provided no values on clinical samples due to unsatisfactory DNA 
quality, while this problem was not noticed using our semi-quantitative method.  
3.3. EBV Serology 
Serology for Epstein-Barr virus was tested according to Svahn et al. [32]. Titration of serum 
antibodies to EA and VCA was performed using the EBV-positive cell line B 95-8 as target. 
Antibodies against EBNA1 proteins were performed using an ELISA against peptide p107 from the 
EBNA 1 sequence. 
3.4. Analysis of Lymphocyte Subsets and HIV-RNA 
Data on subsets of T-lymphocytes, CD4 and CD8, as well as HIV-RNA were obtained by routine 
assays performed in a standardized clinical laboratory.  
3.5. Statistics 
The EBV genome numbers were calculated based on the fraction of positive reactions at each 
dilution according to Reed-Muench [33] and by the Poisson distribution formula, using a method 
originally designed to determine the precursor frequency of antigen-specific T cells [34]. Viruses 2010, 2                  
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4. Conclusions  
In this long term follow up of moderately immune suppressed HIV-infected patients, we observed a 
high individual variation of EBV-DNA levels. cART induced virological control of the HIV-infection 
with undetectable HIV-RNA levels seems to be an insufficient prerequisite for an optimal EBV 
control, as indicated by Gerard et al. [35]. CD4+ cell counts may better reflect the restoration of the 
patient’s control of persisting EBV infection, as suggested by Kostense et al. [36]. This reconstitution 
of the immune system in HIV-infection takes place during one to several years after the introduction of 
cART, as reflected by the continuous increase in CD4+ cell counts [37]. EBV load may therefore be 
considered as a qualitative marker of the actual immune competence in cART treated patients, as also 
suggested for post-transplant patients [18,38]. Although immunological recovery depends on 
suppression of HIV-replication, the recovery of the EBV-host balance is certainly not an immediate 
consequence of the achieved control of HIV. 
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